Tests nasal spray oxymetazoline effect on exercise ability in COPD
Tests a single dose of oxymetazoline nasal spray in adults with COPD.
Key facts
- Who runs it
- Sorlandet Sykehus HF
- Where
- Loerenskog, NorwaySee the site
- Registry title
- An assessment of the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 64 people, planned
- Started
- 4 Oct 2021
- Planned end
- 1 Jan 2026
- Type of study
- Interventional
- Record updated
- 24 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 with COPD (chronic obstructive pulmonary disease). It tests the effect of one dose of oxymetazoline nasal spray (Otrivin®) on physical capacity.
- Age
- 18 to 64 years
- Sex
- Men and women can join.
- Disease stage
- COPD that meets the standard diagnostic criteria of the GOLD standard.
Main reasons for not taking part
- Active malignant disorders
- Other obstructive pulmonary disorders
- Pregnancy
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants who comply with the standard diagnostic criteria for Chronic Obstructive Pulmonary Disease, COPD, as defined in the GOLD standard (Shireen M. 2028)
Who cannot take part
- Active malignant disorders
- Other obstructive pulmonary disorders
- Pragnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Norway
- Akershus University HospitalLoerenskog, NorwayNot yet recruiting
About the trial
What the trial wants to find out
To assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on the physical capacity of patients suffering from Chronic Obstructive Pulmonary Disease (COPD)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- A single group treatment, phase 4, study to assess the effect of 1 dose with oxymetazoline nasal spray(Otrivin®) on physical capacity of males and females aged 18 and 64 years suffering from Chronic Obstructive Pulmonary Disease (COPD)
- Plain-language title
- Tests nasal spray oxymetazoline effect on exercise ability in COPDGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-520177-12-00, who can take part
- Record updated
- 24 January 2025